In a new study in Canada and the US, researchers found one-third of cancer drugs that received accelerated approval from the US Food and Drug Administration (FDA) continue to be recommended in clinical guidelines after their confirmatory clinical trials fail to show improvement on their primary endpoints.
The researchers say clinical guidelines should better align with the results of post-approval trials of cancer drugs that received accelerated approval.
The FDA’s accelerated approval pathway allows drugs onto the market before their effectiveness has been proven to hasten patients’ access to promising new drugs.
But as part of this approval, the manufacturer must conduct post-approval trials to confirm clinical benefit (improved survival or quality of life in the case of cancer drugs).
If these trials show no benefit, the drug’s approval can be withdrawn.
However, post-approval trials can be delayed for several years, and the FDA has until very recently been slow in taking steps to withdraw the drug or indication when these trials are conducted and fail to demonstrate clinical benefit.
In the study, the team examined how the FDA handles cancer drugs that received accelerated approval but had negative post-approval trials, and whether these negative trials change treatment guidelines.
They searched the FDA database for all cancer drugs granted accelerated approval from the start of the program in 1992 until December 2020 and identified 18 indications for 10 cancer drugs that failed to show clinical benefit in post-approval trials.
Of these, the approvals for 11 (61%) were voluntarily withdrawn, one was revoked, and six (33%) remained on the drug’s label, over an average of four years.
The researchers then reviewed the latest FDA and National Comprehensive Cancer Network (NCCN) guidelines.
They found that most of these drugs continued to receive high-level endorsement, sometimes even after approval for the given indication had been withdrawn or revoked.
The findings reflect the lack of fulfillment of the compromise between speed and evidence that underpins the accelerated approval pathway.
They acknowledge that a recent flurry of regulatory action suggests that the FDA has paid greater attention to these situations in the past two years, but call for additional guidance and reforms of the accelerated approval pathway to assure that all FDA-approved drugs are shown to be safe and effective for patients.
If you care about cancer, please read studies about a major cause of deadly brain cancer and findings of this type of diabetes may signal pancreatic cancer.
For more information about cancer and your health, please see recent studies about this common supplement may slightly increase your cancer risk and results showing new evidence that common blood pressure drug may increase skin cancer risk.
The study is published in The BMJ.
Copyright © 2021 Knowridge Science Report. All rights reserved.
